Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 3;9(6):661–673. doi: 10.1002/sctm.19-0220

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. stem cells translational medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

TPO enhances homing of human MNCs to the BM of NOD/SCID mice. A,B, Representative dot plots and percentages of donor human HSPCs (CD45⁺CD34⁺ and CD45⁺CD34⁺CD38⁻) in recipient BMs at 20 hours after cell transplantation. C, Numbers of human CD45⁺CD34⁺ and CD45⁺CD34⁺CD38⁻ cells in the BMs of the mice. n = 5 each. D,E, Representative dot plots and percentages of the donor human CD45⁺ blood cells in the recipients at 4 weeks after transplantation. Mean ± SD, n = 5 for the control group and n = 9 for the TPO treatment group, *P < .05, **P < .01, ***P < .001. TPO treatment group vs control group. BM, bone marrow; HSPC, hematopoietic stem and progenitor cell; MNC, mononuclear cell; NOD/SCID, nonobese diabetic/severe combined immunodeficiency; TPO, thrombopoietin